Q-omics provides the consensus-scored ZNF48 profile across patient tissues and cancer cell-line models. ZNF48 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, ZNF48 is differentially expressed in 14, with the highest sampling consensus in KIRP. Additionally, ZNF48 RNA expression shows 19,490 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UVM, KIRP, and ACC as cancer lineages where ZNF48 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF48 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF48 survival associations across molecular data types. ZNF48 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (4) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF48 RNA expression–survival associations across cancer types. High ZNF48 expression shows unfavorable associations in MESO and LIHC, but favorable associations in UVM, HNSC, KIRC and UCEC. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for ZNF48 RNA expression.
This table summarizes ZNF48 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRP for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for ZNF48. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF48 shows higher tumor expression in KIRP, COAD, LIHC, LUAD, HNSC and BRCA. The KIRP box plot shows higher ZNF48 RNA expression in tumor versus normal tissue (log2 FC = +1.569, t-test p < 0.001).
This table shows molecular features associated with ZNF48 in patient tissues and cancer cell lines. In patient samples, ZNF48 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF48 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUSC, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BLOOD_Leukemia.
